StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for KYTX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $10.72 | $10.74 | +0.19% | 0.9M |
| 05-15 | $10.72 | $9.49 | -11.47% | 1.2M |
| 05-18 | $9.34 | $8.54 | -8.57% | 1.4M |
| 05-19 | $8.51 | $8.70 | +2.23% | 1.0M |
| 05-20 | $8.70 | $8.57 | -1.49% | 0.8M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.